Chris Boshoff: European Commission Approves Pfizer’s RSV Vaccine
Chris Boshoff, Chief Oncology Officer and President of Research and Development at Pfizer, shared a post on LinkedIn:
“I’m pleased to share that the European Commission has approved our respiratory syncytial virus (RSV) vaccine to help prevent RSV in adults aged 18 and older. This expands the previous authorization from individuals aged 60 and older, and our vaccine now offers the broadest RSV vaccine indication in the EU.
Read our press release here.
RSV disease is a common respiratory virus with symptoms that can be severe or even life-threatening, and it causes approximately 158,000 hospital admissions annually among adults aged 18 and older across the EU. This expanded authorization in the EU is an important step for public health by offering the potential to substantially reduce the burden of RSV in future seasons.
Thank you to the entire Pfizer team for their contributions to this important approval!”
More posts featuring Chris Boshoff.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023